SINGAPORE, Sept. 15, 2022 /PRNewswire/ — GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK) and GenScriptProBio (a world one-stop CDMO from GenScript Group) obtain 3 awards: Best Cell & Gene Therapy Supplier Award – Gene Editing on the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) and Best Biologics CMO Awards: Upstream Processing and Analytical Services on the Asia Pacific Biologics CMO & CDMO Excellence Awards (APBCEA) 2022. This is the primary time for GenScript to be acknowledged in these awards in Asia Pacific area.
“Cell and gene therapy is the forefront of innovation and the game changer to bring lights for severe and rare disease patients. With our extensive experiences and matured proprietary technologies for genome editing, we are dedicated to provide the best gene editing services to help in target identification and lead validation stages.” stated Dr. Leo Li in the course of the award ceremony. “This award is a solid testament for GenScript’s 20 years of R&D investment and experiences to provide gene editing service to our partners globally. We are glad that our efforts have been recognized by the panel of judges and peers and we will continue to strive for excellence.”
Both the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 Biologics CMO & CDMO Excellence Awards 2022 acknowledges distinctive bioprocessing specialists, CMO & CDMO organizations and applied sciences that facilitate biomanufacturing and biologics manufacturing excellence at enhanced velocity, decreased value, and superior high quality. This 12 months, GenScript and GenScript ProBio have emerged as award winners for 3 awards.
“We are honored to be recognized by our customers and industry peers as the leading biologics CMO service partner for upstream processing and analytical services in Asia Pacific. This award recognizes our continuous effort and dedication to maintain our global position as the top solutions and service provider to accelerate drug development, next generation vaccines and therapies”, stated Dr. Sharon Du, Director of Business Development, GenScript ProBio Asia Pacific division. “Aside from upstream processes and analytical services, GenScript Probio can provide downstream process development as well, making it a one stop solution for customer. We will continue to provide the best solution to our customers and partners by leveraging our technology platforms and expertise.”
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is the world’s main know-how and service supplier of life science R&D and manufacture. Built upon its stable gene synthesis know-how, GenScript Biotech is split into 4 main platforms together with the life science service and product platform, the biologics contract growth and manufacturing group (CDMO) platform, the worldwide cell remedy platform and the economic synthesis organic product platform.
GenScript Biotech was based in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 100 nations and areas worldwide with authorized entities situated within the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech supplies premium, handy and dependable providers and merchandise for over 100,000 clients.
As of December 31, 2021, GenScript Biotech had greater than 5,200 staff globally, over 40% of whom maintain grasp’s and/or Ph.D. levels. In addition, GenScript Biotech owns quite a lot of mental property rights, together with over 180 patents, over 670 pending patent functions and nice numbers of commerce secrets and techniques.
Driven by the company mission of “making people and nature healthier through biotechnology”, GenScript Biotech strives to develop into essentially the most reliable biotech firm on the planet. As of December 31, 2021, GenScript Biotech’s providers and merchandise have been cited by 65,600 peer-reviewed journal articles worldwide.
For extra info, please go to GenScript Biotech’s official web site.
https://www.genscript.com
About GenScript ProBio
GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively offering end-to-end CDMO service from drug discovery to commercialization with proactive methods, skilled options and environment friendly processes in cell and gene remedy (CGT), vaccine, biologics discovery and antibody protein drug to speed up drug growth for patrons. GenScript ProBio has established corporations in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and different locations to serve world clients, and supported clients in the United States, Europe, Asia Pacific and different areas to acquire greater than 30 IND approvals.
GenScript ProBio’s complete cell and gene remedy resolution covers CMC of plasmid and virus for IND submitting in addition to scientific manufacturing and business manufacturing.
GenScript ProBio’s revolutionary options for biologics discovery and growth embrace therapeutic antibody discovery, antibody engineering and antibody characterization. In biologics growth service, GenScript ProBio has constructed a DNA to GMP materials platform, together with steady cell line growth, host cell license, course of growth, analytical growth to scientific manufacturing, and supply fed-batch and perfusion course of to satisfy the rising wants for antibody and protein medicine. GenScript ProBio has established GMP capability which meets FDA, EMA and NMPA regulatory necessities.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is dedicated to serving to clients shorten the timeline for the event of organic medicine from discovery to commercialization, considerably reducing R&D prices and constructing a more healthy future.
https://www.genscriptprobio.com/
